The precision medicine company leverages AI to improve personalized treatments and outcomes.
GNS Healthcare today announced a $23 million Series D funding round, which could help the company to deliver on increasing consumer demand for care personalization in new and more effective ways.
Cigna Ventures led the financing round, with additional investments from Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments and Gary Loveman, Aetna division president.
“GNS aligns with our vision, and together we can super-charge our advanced analytics capabilities and provide even deeper, more predictable insights that will further enhance customer access to the highest-quality treatment and care, in the preferred and appropriate place, at the right time,” said Tom Richards, global lead of strategy and business development at Cigna.
A precision medicine company, GNS leverages artificial intelligence to help biopharmaceutical companies better understand human diseases and which treatments work for each individual patient. Its causal learning and stimulation platform, Reverse Engineering and Forward Stimulation (REFS), uses clinical trial and real-world data to improve personalized care, medicine and health outcomes.
“As one of the largest and most forward-thinking global health service companies, Cigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables,” said Colin Hill, chairman, CEO and co-founder of GNS Healthcare.
The latest funding round brings the Massachusetts-based company’s financing to $61 million, a GNS spokesperson told Inside Digital Health™.
Precision medicine allows doctors to tailor the treatment to help patients based on the genetic understanding of their disease. This approach is seen particularly in cancer research.
Companies like Cota are using analytics and technology to improve cancer care. In fact, Cota and the U.S. Food and Drug Administration Information Exchange and Data Transformation Program recently signed a research collaboration agreement to better understand the broader treatment of cancer.
And Verily, Google’s life-sciences sister company, partnered with Verve Therapeutics to develop new gene editing delivery platforms which could improve outcomes for individuals at an increased risk of diseases.
Get the best insights in digital health directly to your inbox.
Microdrop Says It Has Succeeded Where Theranos Famously Failed
Researchers Identify Common Genes Linked with Diseases
Genetic Test Detects Hundreds of Harmful Mutations in High-Risk Populations